Norges Bank bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 125,551 shares of the specialty pharmaceutical company's stock, valued at approximately $4,540,000. Norges Bank owned 0.23% of Supernus Pharmaceuticals at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in SUPN. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $52,000. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $72,000. Venturi Wealth Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $92,000. Finally, KBC Group NV grew its holdings in shares of Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock valued at $97,000 after acquiring an additional 929 shares in the last quarter.
Insider Buying and Selling
In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is owned by company insiders.
Supernus Pharmaceuticals Price Performance
SUPN traded up $0.18 during trading on Tuesday, hitting $31.78. The stock had a trading volume of 44,154 shares, compared to its average volume of 490,936. The company has a 50 day moving average price of $33.37 and a 200-day moving average price of $35.07. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 29.69 and a beta of 0.90.
Analyst Upgrades and Downgrades
Several research analysts recently commented on SUPN shares. StockNews.com cut Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, April 9th. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
Read Our Latest Stock Report on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
